全文获取类型
收费全文 | 205163篇 |
免费 | 41637篇 |
国内免费 | 7844篇 |
专业分类
耳鼻咽喉 | 3266篇 |
儿科学 | 4992篇 |
妇产科学 | 3507篇 |
基础医学 | 11762篇 |
口腔科学 | 6751篇 |
临床医学 | 41695篇 |
内科学 | 36515篇 |
皮肤病学 | 4467篇 |
神经病学 | 16121篇 |
特种医学 | 6938篇 |
外国民族医学 | 21篇 |
外科学 | 24665篇 |
综合类 | 25245篇 |
现状与发展 | 65篇 |
一般理论 | 9篇 |
预防医学 | 24195篇 |
眼科学 | 4878篇 |
药学 | 14667篇 |
197篇 | |
中国医学 | 9111篇 |
肿瘤学 | 15577篇 |
出版年
2024年 | 930篇 |
2023年 | 6514篇 |
2022年 | 5093篇 |
2021年 | 7911篇 |
2020年 | 9590篇 |
2019年 | 5209篇 |
2018年 | 10033篇 |
2017年 | 10867篇 |
2016年 | 10982篇 |
2015年 | 12857篇 |
2014年 | 16665篇 |
2013年 | 18844篇 |
2012年 | 13425篇 |
2011年 | 13759篇 |
2010年 | 14701篇 |
2009年 | 15787篇 |
2008年 | 10821篇 |
2007年 | 9615篇 |
2006年 | 10156篇 |
2005年 | 7527篇 |
2004年 | 5349篇 |
2003年 | 4677篇 |
2002年 | 3849篇 |
2001年 | 4119篇 |
2000年 | 2932篇 |
1999年 | 2947篇 |
1998年 | 2711篇 |
1997年 | 2539篇 |
1996年 | 2447篇 |
1995年 | 2091篇 |
1994年 | 1483篇 |
1993年 | 1133篇 |
1992年 | 943篇 |
1991年 | 794篇 |
1990年 | 655篇 |
1989年 | 649篇 |
1988年 | 606篇 |
1987年 | 467篇 |
1986年 | 412篇 |
1985年 | 368篇 |
1984年 | 289篇 |
1983年 | 317篇 |
1982年 | 245篇 |
1981年 | 225篇 |
1980年 | 136篇 |
1978年 | 128篇 |
1977年 | 134篇 |
1976年 | 94篇 |
1974年 | 87篇 |
1972年 | 93篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
目的探讨脊髓小脑共济失调2型(SCA2)致病基因ATXN2异常等位基因中间重复个体的表型和分子遗传学特点。方法针对2005—2018年中日友好医院神经科运动障碍与神经遗传病研究中心收集的1383个常染色体显性遗传共济失调家系的先证者和部分家系成员,采用荧光标记毛细管电泳片段分析方法进行动态突变检测,对携带ATXN2基因中间重复的个体进行临床表型和遗传特征分析。结果共检出163个家系(包含先证者和家系成员共203人)携带异常扩展的ATXN2基因CAG重复序列,其中93个家系中有107例的异常扩展等位基因重复次数在29~34次之间。在其中的20个亲子对中,父系遗传16个,异常等位基因的代间扩展增加0~28次,母系遗传4个,异常等位基因的代间扩展增加0~4次。结论对于临床拟诊SCA2家系患者,需对其亲代或成年子代个体进行ATXN2基因检测,以免漏诊。动态突变基因检测有助于识别中间重复的个体,对明确家系致病基因和遗传咨询至关重要。 相似文献
12.
13.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献
14.
15.
16.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
17.
黄莺 《云南中医学院学报》2022,(2):28-32
本草学是东方医药学的重要标志。在生境中辨识药用植物是本草学的重点,本草著作在对药用植物进行描述的同时,基于知识传授的实际需要,会配以药图帮助学者掌握该药材的特点以方便识别。药图在发展过程中逐渐从本草著作的附属成为独立的册页,其科学和艺术价值也日益凸显,然而其重要性并没有被太多研究者重视,尤其将药图研究的视野从传统医药扩展至文化史、艺术史、美学和文化资源学等领域的研究成果更是鲜有。本文从本草学和本草图谱的演变发展历史为线索,以云南地域本草的杠鼎之作《滇南本草》各时期版本中代表性药图作为研究对象,对比《本草纲目》等几种代表性本草著作中的药图,结合文化和艺术史相关知识,初步梳理《滇南本草》各历史时期药图的特点,分析其演变原因和具体社会条件,尝试从历史角度理解和归纳这些不同时期和版本药图的发展变化呈现的特点并揭示我们今天研究和利用中国传统药图这一重要文化资源的意义和价值。 相似文献
18.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
19.
20.